Search Results - "Sureda‐Balari, Anna"

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study by Hutchings, Martin, Mous, Rogier, Clausen, Michael Roost, Johnson, Peter, Linton, Kim M, Chamuleau, Martine E D, Lewis, David John, Sureda Balari, Anna, Cunningham, David, Oliveri, Roberto S, Elliott, Brian, DeMarco, Dena, Azaryan, Ada, Chiu, Christopher, Li, Tommy, Chen, Kuo-mei, Ahmadi, Tahamtan, Lugtenburg, Pieternella J

“…Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of…”
Get full text

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study by Chari, Ajai, Rodriguez‐Otero, Paula, McCarthy, Helen, Suzuki, Kenshi, Hungria, Vania, Sureda Balari, Anna, Perrot, Aurore, Hulin, Cyrille, Magen, Hila, Iida, Shinsuke, Maisnar, Vladimir, Karlin, Lionel, Pour, Ludek, Parasrampuria, Dolly A., Masterson, Tara, Kosh, Michele, Yang, Shiyi, Delioukina, Maria, Qi, Ming, Carson, Robin, Touzeau, Cyrille

“…Summary Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV) infusion for multiple myeloma (MM). We describe the Phase II PLEIADES…”
Get full text

T001: FDG‐PET and serum TARC levels after one cycle of BV‐AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET‐response adapted EORTC‐COBRA trial by Diepstra, Arjan, Visser, Lydia, Fortpied, Catherine, Noordzij, Walter, Loft, Annika, Arens, Anne, Sureda‐Balari, Anna, Carvalho, Susana, Vranovský, Andrej, Sents, Ward, Buhrer, Emanuel, Plattel, Wouter J., Hutchings, Martin

Get full text

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial by Sureda‐Balari, Anna, Terol, M. José, Domingo‐Domènech, Eva, Rodriguez, Ana Pilar González, Mohedo, Francisca Hernández, Céspedes, Javier Núñez, De La Cruz Vicente, Fátima, Muñoz, Carmen Martínez, Díaz, M. Elena Amutio, Córdoba, Raul, Izquierdo, Antonia Rodríguez, Domínguez, Samuel Romero, Meijide, Javier Briones, Greil, Richard, Velázquez, Miriam Moreno, Rubio, Araceli, Oteiro, Mariana Bastos, Gómez, Pilar, Avivi, Irit, Casanova, María, Del Campo García, Raquel, Noriega, Victor, Blanco, José Javier Sánchez, Sanz, Ramón. García

Get full text

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma by Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe

“…The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant…”
Get full text

Palliative care in patients with haematological neoplasms: An integrative systematic review by Moreno-Alonso, Deborah, Porta-Sales, Josep, Monforte-Royo, Cristina, Trelis-Navarro, Jordi, Sureda-Balarí, Anna, Fernández De Sevilla-Ribosa, Alberto

“…Background: Palliative care was originally intended for patients with non-haematological neoplasms and relatively few studies have assessed palliative care in…”
Get full text

Is Early Palliative Care Feasible in Patients With Multiple Myeloma? by Porta-Sales, Josep, Guerrero-Torrelles, Maria, Moreno-Alonso, Deborah, Sarrà-Escarré, Josep, Clapés-Puig, Victòria, Trelis-Navarro, Jordi, Sureda-Balarí, Anna, Fernández De Sevilla-Ribosa, Alberto

“…Evidence for the benefits of early palliative care (EPC) in patients with solid tumors is strong, but EPC has received scant attention in hematologic…”
Get full text

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma by Hungria, Vania, Robak, Pawel, Hus, Marek, Zherebtsova, Vera, Ward, Christopher, Ho, P. Joy, Ribas de Almeida, Ana Carolina, Hajek, Roman, Kim, Kihyun, Grosicki, Sebastian, Sia, Hanlon, Bryant, Adam, Pitombeira de Lacerda, Marcelo, Aparecida Martinez, Gracia, Sureda Balarí, Anna Maria, Sandhu, Irwindeep, Cerchione, Claudio, Ganly, Peter, Dimopoulos, Meletios, Fu, Chengcheng, Garg, Mamta, Abdallah, Al-Ola, Oriol, Albert, Gatt, Moshe E., Cavo, Michele, Rifkin, Robert, Fujisaki, Tomoaki, Mielnik, Michał, Pirooz, Nick, McKeown, Astrid, McNamara, Simon, Zhou, Xiangdong, Nichols, Maureen, Lewis, Eric, Rogers, Rachel, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, Mateos, María-Victoria

“…Among patients with relapsed myeloma, median progression-free survival was approximately 3 years with a regimen including belantamab mafodotin, as compared…”
Get full text

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS by Moreau, Philippe, Chari, Ajai, Oriol, Albert, Martinez-Lopez, Joaquin, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, de la Rubia Comos, Javier, Encinas, Cristina, Mateos, Maria-Victoria, Salwender, Hans, Rodriguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda Balari, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, Maria, Goldschmidt, Hartmut

Get full text

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma by Alegre, Adrián, Rubia, Javier, Sureda Balari, Anna, Encinas Rodríguez, Cristina, Suárez, Alexia, Blanchard, María Jesús, Bargay Lleonart, Joan, Rodríguez‐Otero, Paula, Insunza, Andrés, Palomera, Luis, Peñarrubia, María Jesús, Ríos‐Tamayo, Rafael, Casado Montero, Luis Felipe, González, Marta Sonia, Potamianou, Anna, Couturier, Catherine, Pei, Huiling, Hevia, Henar, Milionis, Iordanis, Gaudig, Maren, Mateos, María‐Victoria

“…Supplemental Digital Content is available in the text Daratumumab is a human CD38‐targeted monoclonal antibody approved as monotherapy for heavily pretreated…”
Get full text

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE) by Saccardi, Riccardo, Putter, Hein, Eikema, Dirk-Jan, Busto, María Paula, McGrath, Eoin, Middelkoop, Bas, Adams, Gillian, Atlija, Marina, Ayuk, Francis Ayuketang, Baldomero, Helen, Beguin, Yves, de la Cámara, Rafael, Cedillo, Ángel, Balari, Anna María Sureda, Chabannon, Christian, Corbacioglu, Selim, Dolstra, Harry, Duarte, Rafael F., Dulery, Rémy, Greco, Raffaella, Gusi, Andreu, Hamad, Nada, Kenyon, Michelle, Kröger, Nicolaus, Labopin, Myriam, Lee, Julia, Ljungman, Per, Manson, Lynn, Mensil, Florence, Milpied, Noel, Mohty, Mohamad, Oldani, Elena, Orchard, Kim, Passweg, Jakob, Pearce, Rachel, de Latour, Régis Peffault, Poirel, Hélène A., Rintala, Tuula, Rizzo, J. Douglas, Ruggeri, Annalisa, Sanchez-Martinez, Carla, Sanchez-Guijo, Fermin, Sánchez-Ortega, Isabel, Trnková, Marie, Ferreiras, David Valcárcel, Wilcox, Leonie, de Wreede, Liesbeth C., Snowden, John A.

“…From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide…”
Get full text

Results from the Cohort Expansion Stage of a Phase I Trial of Tinostamustine Monotherapy in Advanced Haematological Malignancies (NCT02576496): Findings from a Subset of Patients with Cutaneous T-Cell Lymphoma (CTCL) by Zinzani, Pier Luigi, Morschhauser, Franck, Janik, Tomas, Manamley, Nick, Hilgier, Kasia, Sureda Balari, Anna Maria

“…Background Tinostamustine, a novel alkylating deacetylase inhibitor, improves drug access to cancer cell DNA strands, breaks them and counteracts damage…”
Get full text

Comprehensive Geriatric Assessment in Diffuse Large B-Cell Lymphomas Patients Older Than 70 Years Old: Prospective Single-Center Experience by Rampi, Nicolo, Antonio, Maite, Domingo Domenech, Eva, Lopez-Pereira, Patricia, De Oliveira, Ana C., Aguilera, Carmen, Sureda Balari, Anna Maria, Gonzalez Barca, Eva Maria

“…Diffuse large B-cell lymphoma (DLBCL) is diagnosed at a median age of 65 years, and around 40% of the patients are older than 70 years. Because of frailty and…”
Get full text

Neurofilaments As Serum Biomarkers of Brentuximabvedotin-Induced Peripheral Neurotoxicity in CD30 + Lymphoma Patients: A Prospective Single-Center Study by Domingo Domenech, Eva, Marco, Carla, Gonzalez Barca, Eva Maria, Muniesa, Cristina, Lopez-Pereira, Patricia, De Oliveira, Ana C., Aguilera, Carmen, Ferrer, German, Sureda Balari, Anna Maria, Velasco, Roser

“…Introduction: Brentuximab vedotin (Bv) is increasingly being used for the treatment of CD30+ lymphomas, being Bv-induced peripheral neurotoxicity (BvPN) one of…”
Get full text

Results from the Cohort-Expansion Stage of a Phase I Trial of Tinostamustine Monotherapy in Advanced Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) (NCT02576496) by Sureda Balari, Anna Maria, Ghesquieres, Herve, Morschhauser, Franck, Mutsaers, Pim, Ocio, Enrique M, Janik, Tomas, Manamley, Nick, Hilgier, Kasia, Zinzani, Pier Luigi

“…Background Tinostamustine, a novel alkylating deacetylase inhibitor, improves drug access to cancer cell DNA strands, breaks them and counteracts damage…”
Get full text

P-335 Iberdomide Is Immune Stimulatory and Induces Deep Anti-Myeloma Activity Across Doses in Combination With Daratumumab in Patients With TNE NDMM From the CC-220-MM-001 Study by Amatangelo, Michael, Wang, Maria, Maciag, Paulo, Balari, Anna Sureda, van de Donk, Niels, Lonial, Sagar, Gandhi, Anita K., Martin, Nathan

Get full text

Thiotepa, Busulfan and Fludarabine Conditioning Regimen in Adult Patients Undergoing Allogeneic Stem Cell Transplantation for Lymphoid Malignancies. a Study on Behalf of Geth-TC by Peña, Marta, Paviglianiti, Annalisa, Pascual, Maria Jesús, Herruzo, Beatriz, Solano, Carlos, Benzaquen, Ana, Salas, Maria Queralt, Rovira, Montserrat, Nieto, Agustin, Español, Ignacio, Sáez Marín, Adolfo Jesús, Bento De Miguel, Leyre, Sureda Balari, Anna Maria, Mussetti, Alberto

“…Background: The optimal conditioning regimen in allogeneic hematopoietic stem cell transplant (alloHCT) for lymphoid malignancies remains unclear. Reduced…”
Get full text

Impact of Front-Line Treatment Interim PET/CT in Peripheral T-Cell Lymphoma Patients' Survival: Experience of a Single Center by Rampi, Nicolo, Cortes-Romera, Montserrat, Lopez-Pereira, Patricia, Martinez-Ramos, Carolina, Montane Carbo, Clara, Arevalo Leon, Carolina Esther, De Oliveira, Ana C., Gonzalez Barca, Eva Maria, Sureda Balari, Anna Maria, Domingo Domenech, Eva

“…Introduction: The introduction of PET/CT in the staging and response assessment to therapy has changed the clinical evaluation of most lymphomas, especially…”
Get full text

LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center by Pomares, Helena, Arribas, Iago, Quiñones, Teresa, Villarreal Hernandez, Jasson, Ribes Amoros, Julia, Maluquer Artigal, Clara, Quiñones, Shiomara, Sotelo, Maria Isabel, Senin, María Alicia, Galiano, Mercedes, Gamundi, Enric, Zamora, Lurdes, Ruiz Xiville, Neus, Sureda Balari, Anna Maria, Arnan Sangerman, Montserrat

“…The combination of azacitidine and venetoclax has become the standard of care in patients with acute myeloid leukemia (AML) who are not eligible for intensive…”
Get full text

Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2 by Brody, Joshua, Joergensen, Judit Mészáros, Belada, David, Costello, Regis T., Trněný, Marek, Vitolo, Umberto, Lewis, David, Karimi, Yasmin H., Sureda Balari, Anna Maria, André, Marc, Wahlin, Björn E., Lugtenburg, Pieternella, Galderisi, Faith, Abbas, Aqeel, Song, Yaou, Risum, Malene, Cordoba, Raul

“…Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who fail or are ineligible for autologous stem cell transplant (ASCT)…”
Get full text